{"url_path":"/sec/phio/8-k/2026-07-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/1533040/0001437749-26-023916-index.html","accession_number":"0001437749-26-023916","cik":"0001533040","ticker":"PHIO","issuer_name":"Phio Pharmaceuticals Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1533040/0001437749-26-023916-index.html","primary_entity_key":"0001533040","primary_entity_name":"Phio Pharmaceuticals Corp."},"word_count":88,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit No.**\n\n \n\n**Description**\n\n99.1\n\n \n\n[Press release issued by the Company on July 21, 2026. ](ex_989635.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n2\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n**PHIO PHARMACEUTICALS CORP.**\n\n \n \n\n \n \n \n\nDate: July 21, 2026\n\nBy:\n\n/s/ Robert J. Bitterman\n\n \n \n\nRobert J. Bitterman\n\nPresident & Chief Executive Officer\n\n \n\n \n\n3"}